Application for Short-Term Trainee at BRIC-NABI
2 June 2026

Application for Short-Term Trainee at BRIC-NABI

A registered students from any branches of life sciences/basic sciences/applied sciences/engineering institutes/colleges/universities pursuing post-graduation or having degrees in the above are eligible for BRIC-NABIs training programs. BRIC-NABI
2 June 2026
Call for Research Associate Position at NIPGR - Life Sciences apply now
Candidates having a doctorate (Ph. D) degree in Life Sciences or equivalent (including Molecular Biology, Biochemistry, Plant Physiology) with a good publication record and fulfilling the DST/SERB guidelines as per DST-OM number DST/PCPM/Z-06/2022 dated June 26, 2023 are eligible to apply.  BRIC-NIPGR
2 June 2026
Walk In Drive at Vadodara for Pharma and Science candidates in Quality Function, Production and Packing at Alembic Pharma
Operate & manage granulation, compression, coating, pelletization and capsule filling area. Operate and monitor pharmaceutical manufacturing equipment as per SOPs, BMRs, and GMP guidelines. Alembic Pharmaceuticals
2 June 2026
Amneal Pharmaceuticals Openings : Jobs in QC, Manufacturing & Packing
Perform analysis of raw materials and in process finished products using UV, IR, HPLC, UPLC, GC, LCMS, etc. Amneal Pharmaceuticals
2 June 2026
Ipca Lab Hiring Pharma and Science Freshers in Production / QA / QC
M.Sc./B.Sc./M.Tech/B.tech /Diploma/ITI ; Microbiology/ Biotech/Chemistry/ Biochemistry/ Pharmacy. Ipca Lab
2 June 2026
Production, Quality Control and Warehouse Jobs at Unichem Laboratories
Founded by Late Mr. Amrut Mody, Unichem Laboratories Ltd. is one of Indias most respected pharmaceutical companies committed to deliver better health through superior products.
2 June 2026
Interview for Pharma and Science candidates at JDM Research | Multiple Openings
Conduct Experiments, Literature Search, Process Development & Scale-up Preferably from CRO / CDMO Industry. JDM Research
2 June 2026
FDA Approves Shionogi’s Xocova as First Oral Drug to Prevent COVID-19 After Exposure

The U.S. Food and Drug Administration (FDA) has approved Xocova (ensitrelvir), developed by Japanese pharmaceutical company Shionogi & Co., for the prevention of COVID-19 following exposure to an infected individual. The approval makes Xocova the first and only oral antiviral therapy authorized in the United States for post-exposure prophylaxis of COVID-19.

2 June 2026
Study Questions Routine Antibiotic Use After Pediatric Appendicitis Surgery

A new review suggests that routinely prescribing antibiotics after hospital discharge may provide little benefit for children recovering from complicated acute appendicitis (CAA). The findings add to growing concerns about unnecessary antibiotic exposure and its potential role in adverse effects and antimicrobial resistance.

2 June 2026
Five-mRNA Therapy Shows Potential to Prevent Heart Failure After Heart Attack

Researchers from The University of Osaka have developed an innovative mRNA-based treatment that could help protect the heart from long-term damage following a heart attack. In a new study, scientists found that delivering a combination of five therapeutic mRNAs directly to damaged heart tissue significantly improved heart function and survival in mice that had experienced myocardial infarction (heart attack).